Pantoprazole
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
A proton pump inhibitor commonly used in both oral and intravenous formulations for the treatment of erosive esophagitis associated with GERD, Zollinger-Ellison syndrome, and pathological hypersecretory conditions. Pantoprazole is frequently used in hospital settings due to its IV availability.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
A proton pump inhibitor commonly used in both oral and intravenous formulations for the treatment of erosive esophagitis associated with GERD, Zollinger-Ellison syndrome, and pathological hypersecretory conditions. NutriStack rates the supporting evidence as strong. Common adult dosing is 20–40 mg once daily for 4–8 weeks; up to 240 mg/day for hypersecretory conditions (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete magnesium, vitamin b12, calcium. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: healing of erosive esophagitis, maintenance therapy for erosive esophagitis, treatment of pathological hypersecretory conditions. 10 sources indexed (2004–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Covalently binds to the hydrogen/potassium ATPase (H+/K+ ATPase) enzyme system at the secretory surface of gastric parietal cells, irreversibly inhibiting the final step of gastric acid production. Its selectivity for cysteine 822 on the proton pump provides sustained acid suppression.
Dosing & protocol.
Take 30 minutes before a meal; swallow tablets whole, do not crush or chew
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Magnesium
SignificantChronic acid suppression impairs active intestinal magnesium transport, especially via TRPM6/7-mediated uptake.
Vitamin B12
ModerateReduced gastric acid impairs release of food-bound vitamin B12 from proteins, lowering long-term absorption.
Calcium
ModerateLower gastric acidity reduces dissolution and absorption of less-soluble calcium salts, especially calcium carbonate.
Iron
ModerateReduced gastric acidity lowers conversion and solubility of non-heme iron, decreasing long-term absorption.
Full safety detail.
Side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Flatulence
- Injection site reactions (IV form)
- C. difficile-associated diarrhea
- Hypomagnesemia with prolonged use
- Vitamin B12 deficiency with long-term use
- Increased risk of bone fractures with long-term use
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
1- 1Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysisPMIDGisbert JP, Khorrami S, Calvet X et al. · European journal of gastroenterology & hepatology · 2004
Gisbert JP, Khorrami S, Calvet X et al.. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. European journal of gastroenterology & hepatology. 2004
Randomized controlled trials
2- 2Comparative Efficacy of Dexlansoprazole, Pantoprazole, Esomeprazole, and Rabeprazole in Achieving Optimal 24-Hour Intragastric pH Control: A Randomized Crossover Study Using Ambulatory pH MonitoringPMIDJalihal U, Mahapatra JR, Kumar A et al. · Cureus · 2024
Jalihal U, Mahapatra JR, Kumar A et al.. Comparative Efficacy of Dexlansoprazole, Pantoprazole, Esomeprazole, and Rabeprazole in Achieving Optimal 24-Hour Intragastric pH Control: A Randomized Crossover Study Using Ambulatory pH Monitoring. Cureus. 2024
- 3Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory StudyPMIDSelvanderan SP, Summers MJ, Finnis ME et al. · Critical care medicine · 2016
Selvanderan SP, Summers MJ, Finnis ME et al.. Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study. Critical care medicine. 2016
Reviews & position papers
1- 4Clozapine and norclozapine pharmacokinetic interaction with pantoprazolePMIDAlbitar O, Harun SN, Ghadzi SMS · British journal of clinical pharmacology · 2026
Albitar O, Harun SN, Ghadzi SMS. Clozapine and norclozapine pharmacokinetic interaction with pantoprazole. British journal of clinical pharmacology. 2026
Observational studies
1- 5Safety of Intravenous Pantoprazole Sodium in Pediatric Patients Aged 1 Month to < 1 Year: A Real-World Retrospective Cohort StudyPMIDGandhi S, Taylor B, Rubens L et al. · Therapeutic innovation & regulatory science · 2024
Gandhi S, Taylor B, Rubens L et al.. Safety of Intravenous Pantoprazole Sodium in Pediatric Patients Aged 1 Month to < 1 Year: A Real-World Retrospective Cohort Study. Therapeutic innovation & regulatory science. 2024
Reference material
5- 6Freedberg DE et al. The risks and benefits of long-term use of proton pump inhibitors. BMJ. 2017.Source linkedPMID
- 7Cheer SM et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003.Source linkedPMID
- 8Floria DE et al. Proton pump inhibitors are not associated with an increased risk of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials. Gut Microbes. 2025.Source linkedPMID
- 9Krag M, Marker S, Perner A et al.. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. The New England journal of medicine. 2018Source linkedPMID
- 10Pantoprazole. 2006Source linkedPMID
Common questions.
Quick answers about Pantoprazole, drawn from the data on this page.
What is Pantoprazole?
A proton pump inhibitor commonly used in both oral and intravenous formulations for the treatment of erosive esophagitis associated with GERD, Zollinger-Ellison syndrome, and pathological hypersecretory conditions. Pantoprazole is frequently used in hospital settings due to its IV availability.
What is Pantoprazole used for?
Commonly cited benefits of Pantoprazole include: Healing of erosive esophagitis; Maintenance therapy for erosive esophagitis; Treatment of pathological hypersecretory conditions; Stress ulcer prophylaxis (IV formulation); Reduction of gastric acid in Zollinger-Ellison syndrome. NutriStack rates the overall evidence as strong.
What is a typical dose of Pantoprazole?
A typical adult dose of Pantoprazole is 20–40 mg once daily for 4–8 weeks; up to 240 mg/day for hypersecretory conditions (as prescribed by your physician). The commonly recommended form is Delayed-release tablet or IV injection. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Pantoprazole?
Reported side effects include headache, diarrhea, nausea, abdominal pain, vomiting, flatulence. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Pantoprazole?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Pantoprazole in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.